Vivos Therapeutics, Inc.
VVOS
$2.63
-$0.08-2.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.85% | 16.93% | 19.41% | -11.36% | -17.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.85% | 16.93% | 19.41% | -11.36% | -17.77% |
| Cost of Revenue | 38.14% | -1.80% | 8.17% | -2.50% | -25.99% |
| Gross Profit | 0.38% | 33.60% | 26.36% | -17.12% | -12.37% |
| SG&A Expenses | -21.64% | -7.71% | -31.31% | -22.20% | -24.82% |
| Depreciation & Amortization | -3.36% | -2.67% | -2.03% | -16.57% | -11.83% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.88% | -6.28% | -24.29% | -18.71% | -26.29% |
| Operating Income | 32.11% | 27.34% | 57.14% | 24.38% | 31.83% |
| Income Before Tax | 33.62% | -24.99% | 65.09% | -120.96% | 30.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 33.62% | -24.99% | 65.09% | -120.96% | 30.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.62% | -24.99% | 65.09% | -120.96% | 30.05% |
| EBIT | 32.11% | 27.34% | 57.14% | 24.38% | 31.83% |
| EBITDA | 33.18% | 28.42% | 59.01% | 24.66% | 32.41% |
| EPS Basic | 86.97% | 65.06% | 87.05% | 5.16% | 44.13% |
| Normalized Basic EPS | 86.97% | 65.06% | 87.05% | 5.17% | 44.33% |
| EPS Diluted | 86.97% | 65.06% | 87.05% | 5.16% | 44.13% |
| Normalized Diluted EPS | 86.97% | 65.06% | 87.05% | 5.17% | 44.33% |
| Average Basic Shares Outstanding | 409.47% | 257.65% | 169.64% | 132.99% | 25.19% |
| Average Diluted Shares Outstanding | 409.47% | 257.65% | 169.64% | 132.99% | 25.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |